Indian Clinical Research Industry
- 1. STATISTICAL REVIEW OF CLINICAL RESEARCH INDUSTRY By GEETANJALI PARAB PRIYANKA MUDLIAR SHIVANGI PATIL SRABANI BISWAS TANMAY SHINDE CLASS- PGDAIB 04/01/10
- 2. INTRODUCTION Clinical research may be defined as organized research conducted on human beings intended to provide adequate information on drug use as a therapeutic agent on its safety ,efficacy and its adverse effects. Globally there is a paradigm shift in the pharmaceutical market & nearly two third of R& D costs go into drug development . Of this,70% time and resources are spent in clinical research. 04/01/10
- 3. Overall country attractiveness index in clinical research 04/01/10
- 4. U.S. SPONSORED CLINICAL TRIALS MARKET, 2003-2011($BILLIONS) 04/01/10
- 5. Country share of registered clinical trials in Asia India is close second to China (~41%) with 36% clinical trials being registered from 2002 to 2008. Singapore and Pakistan holds third and fourth position respectively in 5 nations comparison study. Sri Lanka has only 0.3% share in the pie. 04/01/10
- 6. Clinical trials in Asia on a rise India - 463.33% growth from 2002 to 2008 in terms of clinical trials . China - second with 365.56% rise in the same period. Overall statistics -China remains number 1 for clinical trial destination amongst 4 countries. 04/01/10
- 8. Why India A Choice For CR ??? 04/01/10
- 9. Evolution of CR in INDIA 1995-2015 04/01/10
- 10. Therapeutic area wise distribution 04/01/10
- 11. Clinical Studies for USFDA Submission (India) 04/01/10
- 12. Clinical Research market size 04/01/10
- 13. Clinical Research Segmental Players in INDIA 04/01/10
- 14. Clinical trials conducted by MNC’s 04/01/10
- 15. MARKET SHARE OF CROs 04/01/10
- 16. Estimated CR Industry Growth in INDIA 04/01/10
- 17. Revenue Record 04/01/10 Projected figures in respect of revenue, human power and patient load for clinical research in India 2003 2008 2010 Value (million USD) 50 200 1000 Revenue (crore INR) 75 300 875 Full time staff requirement 800 4000 20,000 Site-staff requirement 1500 6000 30,000 Patient load 10,000 50,000 300,000 Source: McKinsey report
- 18. Various Job Sectors for CR in INDIA 04/01/10
- 19. SCOPE AND FUTURE 04/01/10
- 20. Demand –Supply Gap in INDIA 2010 04/01/10
- 21. SCOPE The forecasted size of the clinical research market in India by 2010 varies from $300 million (Ernst & Young) to $1.5-$2 billion (McKinsey). This range reflects India's potential to be a major global player in clinical trials. India is fast-emerging as an attractive destination for clinical trials. Today, the market value of clinical research outsourced to India is estimated at more than US$300 million compared with US$ 140 million in 2006 and it is expanding at 40% over last 3 years. By 2010, it is projected to be of US$1.5 – 2.0 billion. In 2005% only 1% of the global trials were conducted in India and it is expected to conduct 15% of the global trials by 2011. The matter of fact is that, India's clinical research industry is still relatively small in size compared to the global clinical trial industry estimated at around $30 billion. 04/01/10
- 22. OPPORTUNITIES IN CR India has 300 universities, over 750 graduate and post-graduate programs, and about 50 million collage graduates. Presently there are only 40 institutes offer courses in clinical research and provide 5000 trained professionals annually. This is inadequate as industry needs approximately 11,000 professionals annually. By 2011, India will require 50,000 professionals to support its booming CR industry. 04/01/10 1. INDIA Vital Stats 2. No. of universities: 300 3. No. of graduate / post-graduate programs offered: 750 4. No of graduate students: 50mn 5. No. of CR professionals trained / yr: 5000 6. No. of CR professionals required / yr: 11000 7. No. of medical professionals: 7, 00,000 8. No. of ICH-GCP trained investigators: 1000
Editor's Notes
- #5: By 2020, the pharmaceutical market is anticipated to more than double to $1.3 trillion. TRENDS National spending on clinical trials was nearly $24 billion in 2005. By 2006 this number will rise to $25.6 billion and then $32.1 billion in 2011, an average annual growth rate (AAGR) of 4.6%. In 2005, biotechnology and pharmaceutical companies spent approximately $51 billion on research and development efforts, with $21 billion (41%) spent on clinical trials. In comparison, government contributions to clinical trials were considerably smaller. The National Institutes of Health spent $2.9 billion on clinical trials in 2005 and budgeted $3.0 billion for 2006. Total funding for 2005 was $24.4 billion. In 2006 this number will rise to $26 billion and in 2011 to $32.6 billion, an AAGR of 4.6% The number of clinical trials performed in 2005 was 8,386. BCC Research predicts this number will reach almost 10,000 by 2006. At an AAGR of 5.8%, the number of clinical trials performed in 2011 will reach more than 13,000.
- #6: Clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices. A comparative study for key Asian countries (India, China, Pakistan, Singapore and Sri Lanka) to better understand the trend of clinical trials in Asian countries. The numbers of trials, as registered with clinicaltrials.gov by companies all across the world were considered in this study.
- #7: As apparent from our results India and China were head to head till the year 2006, following that China started getting lead from India. On the other hand, Singapore started losing to India and China following 2004.
- #16: In 2006 the total market for CRO services was estimated to be $15 billion. Of this Covance had a share of 10%, which equated to $1.5 billion. [2] http://www.wikinvest.com/stock/Covance_(CVD)